, Cancer incidence and mortality worldwide: IARC CancerBase No, International Agency for Research on Cancer, 2013.

J. Higginson, The geographical pathology of primary liver cancer, Cancer Res, vol.23, pp.1624-1657, 1963.

F. Wu and P. Khlangwiset, Health economic impacts and cost-effectiveness of aflatoxin reduction strategies in Africa: case studies in biocontrol and postharvest interventions, Food Addit Contam, vol.27, pp.496-509, 2010.

J. Ott, G. Stevens, and S. Wiersma, The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions, BMC Infect Dis, vol.12, p.131, 2012.

J. Yang, E. A. Mohamed, A. Abdelaziz, H. Shousha, M. Hashem et al., Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium, Lancet Gastroenterol Hepatol, vol.2, pp.103-114, 2017.

B. Bressac, M. Kew, J. Wands, and M. Ozturk, Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa, Nature, vol.350, pp.429-460, 1991.

P. Pineau, A. Marchio, C. Battiston, E. Cordina, A. Russo et al., In human hepatocellular carcinoma, chromosome instability depends on p53 status and aflatoxin exposure, Mutat Res, vol.653, pp.6-13, 2008.

A. Tanase, A. Marchio, T. Dumitrascu, S. Dima, V. Herlea et al., Mutation spectrum of hepatocellular carcinoma from Eastern-European patients betrays the impact of a complex exposome, J Exp Sci Environ Epidemiol, vol.25, pp.256-63, 2014.

A. Marchio, J. P. Cerapio, E. Ruiz, L. Cano, S. Casavilca et al., Early forms of liver cancer in South America associate with low hepatitis B virus DNA burden

D. Gouas, H. Shi, and P. Hainaut, The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy, Cancer Lett, vol.286, pp.29-37, 2009.

P. Mandel and P. Métais, Les acides nucléiques du plasma sanguin chez l'Homme, CR Soc Biol, vol.142, pp.241-244, 1948.

K. Chan and Y. Lo, Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers, Br J Cancer, vol.96, pp.681-686, 2007.

A. Pathak, M. Bhutani, S. Kumar, A. Mohan, and R. Guleria, Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool, Clin Chem, vol.52, pp.1833-1875, 2006.

C. Bettegowda, M. Sausen, R. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, pp.224-248, 2014.

A. Thierry, F. Mouliere, E. Messaoudi, S. Mollevi, C. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071

N. Ladep, O. Lesi, P. Mark, M. Lemoine, C. Onyekwere et al., Problem of hepatocellular carcinoma in West Africa, World J Hepatol, vol.6, pp.783-92, 2014.

J. Eng, ROC analysis: web-based calculator for ROC curves, 2014.

A. Atsama, M. , N. Noah, D. , F. Moundipa et al., A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa, BMC Infect Dis, vol.16, p.647, 2016.

C. Wild and R. Montesano, A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention, Cancer Lett, vol.286, pp.22-30, 2009.

R. Montesano, P. Hainaut, and C. Wild, Hepatocellular carcinoma: from gene to public health, J Natl Cancer Inst, vol.89, pp.1844-51, 1997.

S. Hussain and C. Harris, p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer, Mutat Res, vol.428, pp.23-32, 1999.

S. Olmedillas-lópez, M. García-arranz, and D. García-olmo, Current and emerging applications of droplet digital PCR in oncology, Mol Diagn Ther, vol.21, pp.493-510, 2017.

M. Ku?, A. Ossowski, and G. Zieli?ska, Comparison of three different DNA extraction methods from a highly degraded biological material, J Forens Leg Med, vol.40, pp.47-53, 2016.

M. Feldman, I. Hershkovitz, E. Sklan, K. Bar-gal, G. Pap et al., Detection of a tumor suppressor gene variant predisposing to colorectal cancer in an 18th century Hungarian mummy, PLoS ONE, vol.11, p.147217, 2016.

K. Schulze, S. Imbeaud, E. Letouzé, L. Alexandrov, J. Calderaro et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-516, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01159736

G. Kirk, A. Camus-randon, M. Mendy, J. Goedert, M. P. Trepo et al., Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia, J Natl Cancer Inst, vol.92, pp.148-53, 2000.

P. Jackson, G. Qian, M. Friesen, Y. Zhu, P. Lu et al., Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry, Cancer Res, vol.61, pp.33-38, 2001.

H. Unsal, C. Yakicier, C. Marçais, M. Kew, M. Volkmann et al., Genetic heterogeneity of hepatocellular carcinoma, Proc Natl Acad Sci USA, vol.91, pp.822-828, 1994.

A. Marchio, S. Bertani, T. Rojas-rojas, F. Doimi, B. Terris et al., A peculiar mutation spectrum emerging from young Peruvian patients with hepatocellular carcinomas, PLoS ONE, vol.9, p.114912, 2014.

Y. Zhang, Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma, World J Hepatol, vol.2, pp.94-102, 2010.

F. Traoré, E. Gormally, S. Villar, M. Friesen, J. Groopman et al., Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, BMC Infect Dis, vol.15, p.180, 2015.

G. Kimbi, M. Kew, M. Yu, K. Arakawa, and J. Hodkinson, 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma, J Gastroenterol Hepatol, vol.20, pp.1185-90, 2005.

R. Igetei, J. Otegbayo, D. Ndububa, O. Lesi, C. Anumudu et al., Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cellfree DNA, Ann Hepatol, vol.7, pp.339-383, 2008.

A. Tchana, P. Moundipa, and F. Tchouanguep, Aflatoxin contamination in food and body fluids in relation to malnutrition and cancer status in Cameroon, Int J Environ Res Public Health, vol.7, pp.178-88, 2010.

E. Njumbe-ediage, D. D. Mavungu, J. Song, S. Sioen, I. et al., Multimycotoxin analysis in urines to assess infant exposure: a case study in Cameroon, Environ Int, vol.58, pp.50-59, 2013.

W. Abia, B. Warth, M. Sulyok, R. Krska, A. Tchana et al., Bio-monitoring of mycotoxin exposure in Cameroon using a urinary multi-biomarker approach, Food Chem Toxicol, vol.62, pp.927-961, 2013.

G. Kirk, O. Lesi, M. Mendy, K. Szymañska, H. Whittle et al., 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma, Oncogene, vol.24, pp.5858-67, 2005.

M. Lleonart, G. Kirk, S. Villar, O. Lesi, A. Dasgupta et al., Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry, Cancer Epidemiol Biomark Prev, vol.14, pp.2956-62, 2005.

H. El-din, N. Ghafar, N. Saad, M. Aziz, D. Rasheed et al., Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma, Arch Med Sci, vol.3, pp.348-55, 2010.

S. Parpart-li, B. Bartlett, M. Popoli, V. Adleff, L. Tucker et al., The effect of preservative and temperature on the analysis of circulating tumor DNA, Clin Cancer Res, vol.23, pp.2471-2478, 2017.

X. Xue, M. Teare, I. Holen, Y. Zhu, and P. Woll, Optimizing the yield and utility of circulating cell-free DNA from plasma and serum, Clin Chim Acta, vol.404, pp.100-104, 2009.

J. Lu and Z. Liang, Circulating free DNA in the era of precision oncology: pre-and post-analytical concerns, Chron Dis Transl Med, vol.2, pp.223-253, 2016.

M. Fleischhacker, B. Schmidt, S. Weickmann, D. Fersching, G. Leszinski et al., Methods for isolation of cellfree plasma DNA strongly affect DNA yield, Clin Chim Acta, vol.412, pp.2085-2093, 2011.

L. Poulou, E. Botsa, I. Thanou, P. Ziakas, and L. Thanos, Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma, World J Hepatol, vol.7, pp.1054-63, 2015.

J. Mcwilliams, S. Yamamoto, S. Raman, C. Loh, E. Lee et al., Percutaneous ablation of hepatocellular carcinoma: current status, J Vasc Interv Radiol, vol.21, pp.204-217, 2010.